93 related articles for article (PubMed ID: 18827568)
1. Targeting the mammalian target of rapamycin in myxoid chondrosarcoma.
Merimsky O; Bernstein-Molho R; Sagi-Eisenberg R
Anticancer Drugs; 2008 Nov; 19(10):1019-21. PubMed ID: 18827568
[TBL] [Abstract][Full Text] [Related]
2. [Use of cyclophosphane and amphotericin B on patients with disseminated forms of chondrosarcoma].
Lantsman IuV; Adamian AT
Vopr Onkol; 1984; 30(2):31-5. PubMed ID: 6702129
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas.
Bernstein-Molho R; Kollender Y; Issakov J; Bickels J; Dadia S; Flusser G; Meller I; Sagi-Eisenberg R; Merimsky O
Cancer Chemother Pharmacol; 2012 Dec; 70(6):855-60. PubMed ID: 23053256
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM
Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
8. [Morphologic characteristics and differential diagnosis of central mesenchymal chondrosarcoma--an analysis of 15 cases].
Welkerling H; Wolf E; Delling G
Pathologe; 1993 Mar; 14(2):78-83. PubMed ID: 8469649
[No Abstract] [Full Text] [Related]
9. [Case of the successful use of carminomycin in combination with cyclophosphane and vincristine in treating ectopic chondrosarcoma of rare localization in a 5-month-old infant].
Gusev LI; Iasonov AV; Poliakov VG
Antibiotiki; 1978 Jul; 23(7):637-8. PubMed ID: 677854
[TBL] [Abstract][Full Text] [Related]
10. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
Meier F; Guenova E; Clasen S; Eigentler T; Forschner A; Leiter U; Zielinski C; Knaudt B; Garbe C; Berneburg M
J Am Acad Dermatol; 2009 May; 60(5):863-8. PubMed ID: 19389529
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells.
Song J; Wang X; Zhu J; Liu J
J BUON; 2016; 21(1):244-51. PubMed ID: 27061554
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
13. Targeting mTOR in renal cell carcinoma.
Hudes GR
Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.
Jones RL; Katz D; Loggers ET; Davidson D; Rodler ET; Pollack SM
Med Oncol; 2017 Aug; 34(10):167. PubMed ID: 28852958
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
[TBL] [Abstract][Full Text] [Related]
16. A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis.
Hoosien M; Vredenburgh J; Lanfranco J; Ochoa R; Robinson P; Martinez R; Singer C; Silva O
J Neurooncol; 2011 Jan; 101(1):135-9. PubMed ID: 20443130
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
[TBL] [Abstract][Full Text] [Related]
18. Update on chondrosarcomas.
Chow WA
Curr Opin Oncol; 2007 Jul; 19(4):371-6. PubMed ID: 17545802
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.
Kapoor A; Figlin RA
Cancer; 2009 Aug; 115(16):3618-30. PubMed ID: 19479976
[TBL] [Abstract][Full Text] [Related]
20. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
